K&L Gates Adds Former FDA Counsel Christine Kirk As Washington Partner

K&L Gates has appointed Christine Kirk as a partner in its Healthcare and FDA practice group in Washington, D.C. Kirk joins from Peterson Wilmarth and Robertson and brings experience from private practice and nearly six years with the U.S. Food and Drug Administration.

Life Sciences Regulatory Practice

Kirk advises biopharmaceutical companies on regulatory matters spanning early-stage drug development through post-approval compliance.

Her work includes regulatory strategy and intelligence, interactions with federal agencies, legislative analysis, clinical-trial requirements, expedited approval pathways, regulatory exclusivity, real-world evidence, and patient-focused drug development.

Kirk previously served as regulatory counsel in the FDA Center for Drug Evaluation and Research’s Office of Regulatory Policy.

During her government service, she participated in and led working groups focused on federal rules, regulatory guidance, and citizen petitions. She also contributed to congressional responses, Government Accountability Office reports, and FDA public meetings.

Expanding Washington Regulatory Capabilities

Kirk is the latest addition to K&L Gates’ Washington office. Other recent appointments include international trade and national security partner Jeremy Huffman, broker-dealer regulatory partner Tim Foley, government affairs adviser Emily Lavery, government affairs counselor Hayden Haynes, and digital-currency lawyer Sanjeev Bhasker.

K&L Gates has added more than 30 partners and counsel globally since the beginning of 2026.

The firm’s Healthcare and FDA practice advises health systems, academic medical centers, pharmacies, and other healthcare organizations on regulation, fraud and abuse, payer disputes, and contracting.

KEY QUOTES:

Christine brings a valuable combination of private practice and government experience to our Washington office. Her deep understanding of the regulatory issues facing life sciences companies will strengthen our ability to help clients navigate complex and evolving challenges involving the FDA and the broader healthcare sector.

David Wochner, Managing Partner Of K&L Gates’ Washington Office And Regional Managing Partner For The United States

Christine’s firsthand FDA experience, combined with her years of advising life sciences companies on sophisticated regulatory matters, is an important addition to our capabilities. Her perspective across both government and private practice will further enhance the strategic counsel we provide to clients operating in highly regulated industries.

Michael Scanlon, Leader In K&L Gates’ Global Policy And Regulatory Practice

I am excited to join the Healthcare and FDA practice at K&L Gates. The firm has excellent healthcare, policy, and regulatory teams and I look forward to working with my new colleagues to assist life sciences clients.

Christine Kirk, Partner At K&L Gates